The incidence of chronic obstructive pulmonary disease (COPD) and cystic fibrosis is rising across the region. As per the World Health Organization (WHO), exacerbations of COPD are critical events in the history of COPD. Further, COPD-related disability and mortality propel the demand for oscillating positive expiratory pressure (OPEP) devices. Moreover, according to the Center for Disease Control and Prevention (CDC), ~9 million adults were diagnosed with chronic bronchitis in 2018. Further, asthma is becoming common among people of all ages, genders, and races. According to CDC, ~300 million people worldwide have asthma, with an additional 100 million expected by 2025. The prevalence, severity, and mortality of asthma vary dramatically across the US. Asthma affects over 25 million people in the US, which equates to 7.7% of adults and 8.4% of children. Asthma is common in high-income nations, whereas the majority of asthma-related deaths occur in low- and middle-income countries. Therefore, the rising prevalence of COPD and asthma propel the demand for mucous clearing devices, such as OPEP devices, which bolsters the growth of the North America oscillating positive expiratory pressure (OPEP) devices market.
With new features and advanced technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the North America oscillating positive expiratory pressure (OPEP) devices market at a notable CAGR during the forecast period.
North America Oscillating Positive Expiratory Pressure (OPEP) Devices Market Segmentation
The North America oscillating positive expiratory pressure (OPEP) devices market is segmented into product, indication, distribution channel, and country. Based on product, the market is segmented into mouthpiece PEP devices, face mask PEP devices, and bottle PEP devices. In 2021, the mouthpiece PEP devices segment accounted for the largest market share; and it is likely to register the highest CAGR during the forecast period. Based on indication, the market is categorized into chronic obstructive pulmonary disease (COPD), asthma, bronchitis, bronchiectasis, cystic fibrosis, and others. In 2021, the chronic obstructive pulmonary disease (COPD) segment accounted for the largest share of the market; however, the asthma segment is likely to register the highest CAGR during the forecast period. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. In 2021, the hospital pharmacies segment held the largest market share; however, the retail pharmacies segment is expected to register the highest CAGR in the market during the forecast period. Further, based on country, the North America market is segmented into the US, Canada, and Mexico. In 2021, the US held the largest market share; and it is expected to register the highest CAGR during the forecast period.
Allergan Plc.; PARI GmbH; Smiths Medical; AirPhysio; Mercury Medical; D•R BURTON HEALTHCARE; and Medica Holdings, LLC are among some of the leading companies operating in the North America oscillating positive expiratory pressure (OPEP) devices market.